Initial Statement of Beneficial Ownership (3)
January 02 2020 - 4:33PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Daly Sean T |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2020
|
3. Issuer Name and Ticker or Trading Symbol
Anchiano Therapeutics Ltd. [ANCN]
|
(Last)
(First)
(Middle)
C/O ANCHIANO THERAPEUTICS LTD., 5 KIRYAT HAMADA ST., P.O. BOX 45032 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) VP, Clinical Operations / |
(Street)
JERUSALEM, L3 9777401
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee stock options | (1) | 3/4/2028 | Ordinary Shares | 45000 | $4.00 | D | |
Employee stock options | (2) | 5/20/2029 | Ordinary Shares | 35000 | $1.03 | D | |
Explanation of Responses: |
(1) | 1/4 of the options vest one year following the vesting commencement date of March 1, 2018, and 1/16 at the end of each calendar quarter thereafter, until fully vested. |
(2) | 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on May 21, 2019. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Daly Sean T C/O ANCHIANO THERAPEUTICS LTD. 5 KIRYAT HAMADA ST., P.O. BOX 45032 JERUSALEM, L3 9777401 |
|
| VP, Clinical Operations |
|
Signatures
|
/s/ Sean T. Daly | | 1/2/2020 |
**Signature of Reporting Person | Date |
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Jul 2023 to Jul 2024